DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on: October 17,2023

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on:October 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on: December 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on:December 17,2023

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on: October 15,2023

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on:October 15,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on: December 17,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on:December 17,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on: December 18,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on:December 18,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023